Similar companies
Did Zevra Therapeutics Beat Earnings?
Zevra Therapeutics (ZVRA) reported Q2 '26 revenue of $40M, up 53.3% year-over-year, with reported EPS of $0.25. That topped the $0.08 analyst estimate by 212.5% — an earnings beat.
AltIndex tracks earnings alongside 25+ alternative data signals that can move ahead of the report — Zevra Therapeutics’s job postings, web traffic, and employee business outlook. See the full ZVRA stock analysis or the earnings calendar for upcoming reports.
ZVRA Earnings Surprise History (EPS vs. Estimate)
| Quarter | Estimated EPS | Reported EPS | Surprise |
|---|---|---|---|
| Q2 '26 | $0.08 | $0.25 | Beat +212.5% |
| Q1 '26 | $0.08 | $0.18 | Beat +125.0% |
| Q4 '25 | $0.05 | $0.19 | Beat +280.0% |
Zevra Therapeutics Quarterly Financial Trends
| Metric | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.7M | 12M | 20M | 26M | 26M | 34M | 36M | 40M |
| Gross margin | 37.7% | 88.7% | 93.4% | 52.2% | 94.0% | 95.5% | 93.7% | 96.2% |
| Operating margin | -739.0% | -128.0% | -26.3% | -274.5% | 15.9% | 27.3% | 24.4% | 42.3% |
| Net income | -33M | -36M | -3.1M | 75M | -540,000 | 12M | 38M | 8.8M |
| Net margin | -899.2% | -296.8% | -15.2% | 288.7% | -2.1% | 35.6% | 104.6% | 22.1% |
| EPS | — | — | — | — | — | $0.19 | $0.18 | $0.25 |
Zevra Therapeutics Earnings Trend Analysis
Over the eight quarters from Q3 '24 to Q2 '26, Zevra Therapeutics’s quarterly revenue moved from $3.7M to $40M. Net margin expanded from -899.2% to 22.1%, against a 96.2% gross margin in the most recent quarter — a read on whether revenue growth is translating into profit. Zevra Therapeutics has beaten Wall Street EPS estimates in 3 of its last 3 reported quarters.
When Is Zevra Therapeutics’s Next Earnings Date?
Zevra Therapeutics reports earnings on a quarterly schedule. Its most recent report covered Q2 '26. For the confirmed upcoming date — and every other company reporting soon — see the ZVRA earnings calendar.
Frequently Asked Questions: Zevra Therapeutics Earnings
Zevra Therapeutics's next earnings date has not been confirmed yet. See the earnings calendar for all upcoming reports.
Zevra Therapeutics reported Q2 '26 EPS of $0.25 on revenue of $40M (+53.3% YoY). Zevra Therapeutics beat estimates, reporting $0.25 vs. the $0.08 estimate.
Zevra Therapeutics reported Q2 '26 revenue of $40M, up 53.3% from the same quarter a year earlier.
Signals like job postings, web traffic, and employee sentiment reflect business activity in real time and can move before quarterly results are reported. AltIndex combines them with 25+ others in the ZVRA AI Score.
